WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou
SHANGHAI, May 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that construction has been completed on a new biologics biosafety testing facility in Suzhou.
The facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi's GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.
The new services will expand WuXi's already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company's services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.
"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Associate Director of Corporate Communications
SOURCE WuXi PharmaTech (Cayman) Inc.